Literature DB >> 26055607

Necrotising pyomyositis complicating intramuscular antipsychotic administration.

Eugene M Tan1, Jasmine R Marcelin1, Rizwan Sohail1, Kannan Ramar2.   

Abstract

A 26-year-old woman with paranoid schizophrenia was admitted to the medical intensive care unit with septic shock requiring intubation and mechanical ventilation. The source of septic shock was not identified despite obtaining CT of the chest/abdomen/pelvis, bronchoalveolar lavage and microbiological results for tracheal secretions, blood, urine and cervix. An indium-111 tagged white cell count scan was subsequently performed, revealing increased right anterior deltoid uptake. Owing to serial increases (up to 1310 U/L) in serum creatine kinase and a history of local intramuscular paliperidone injections for management of schizophrenia, surgical exploration was performed and identified necrotising skeletal muscle inflammation and extensive fat necrosis with an organising abscess, consistent with pyomyositis. A gram stain of purulent fluid revealed gram-positive cocci, but no organisms grew in culture. The patient recovered after 10 days of daptomycin and 7 weeks of wound care. Paliperidone injections were discontinued and oral risperidone was initiated. 2015 BMJ Publishing Group Ltd.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26055607      PMCID: PMC4460421          DOI: 10.1136/bcr-2015-210017

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  10 in total

Review 1.  Skin and soft tissue infections in injection drug users.

Authors:  John R Ebright; Barbara Pieper
Journal:  Infect Dis Clin North Am       Date:  2002-09       Impact factor: 5.982

Review 2.  A review of compliance, depot intramuscular antipsychotics and the new long-acting injectable atypical antipsychotic risperidone in schizophrenia.

Authors:  Nadeem H Bhanji; Guy Chouinard; Howard C Margolese
Journal:  Eur Neuropsychopharmacol       Date:  2004-03       Impact factor: 4.600

3.  Nicolau syndrome following intramuscular diclofenac injection: a case report.

Authors:  Luigia Panariello; Fabio Ayala
Journal:  Dermatol Ther       Date:  2008-07       Impact factor: 2.851

4.  [Clostridium myonecrosis as a sequelae of intramuscular injections--description of 3 fatal outcomes].

Authors:  C Eckmann; P Kujath; H Shekarriz; K H Staubach
Journal:  Langenbecks Arch Chir Suppl Kongressbd       Date:  1997

Review 5.  Bacterial pyomyositis in the United States.

Authors:  Nancy F Crum
Journal:  Am J Med       Date:  2004-09-15       Impact factor: 4.965

Review 6.  A fatal case of streptococcal toxic shock syndrome due to Streptococcus dysgalactiae subsp. equisimilis possibly caused by an intramuscular injection.

Authors:  Hideharu Hagiya; Shunji Okita; Yasutoshi Kuroe; Hiroyoshi Nojima; Shinkichi Otani; Junichi Sugiyama; Hiromichi Naito; Susumu Kawanishi; Shingo Hagioka; Naoki Morimoto
Journal:  Intern Med       Date:  2013-02-01       Impact factor: 1.271

7.  Bacterial Pyomyositis.

Authors:  Thomas J Scharschmidt; Scott D Weiner; Joseph P Myers
Journal:  Curr Infect Dis Rep       Date:  2004-10       Impact factor: 3.725

Review 8.  Fatal case of toxic shock-like syndrome due to group C streptococcus associated with superantigen exotoxin.

Authors:  Tony M Korman; Anthony Boers; Travis M Gooding; Nigel Curtis; Kumar Visvanathan
Journal:  J Clin Microbiol       Date:  2004-06       Impact factor: 5.948

9.  Tissue necrosis and necrotizing fasciitis after intramuscular administration of diclofenac.

Authors:  P I Pillans; N O'Connor
Journal:  Ann Pharmacother       Date:  1995-03       Impact factor: 3.154

10.  A case of fatal necrotizing fasciitis after intramuscular administration of diclofenac.

Authors:  G Verfaillie; S Knape; L Corne
Journal:  Eur J Emerg Med       Date:  2002-09       Impact factor: 2.799

  10 in total
  1 in total

1.  Unusual Case of Non-HIV Patient With Multifocal Pyomyositis: Developed on Appropriate Antibiotic Therapy.

Authors:  Elisa Akagi; Ashish Bhargava
Journal:  J Med Cases       Date:  2022-08-19
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.